Connect with:
Thursday / November 14. 2024

logo
mobile-logo
HomePosts Tagged "Bill Anderson"
Agribusiness, Agro chems – Chemicals, Agro chems – Fertilizers, Agro chems – Pesticides, Company News, Finance, Inputs, Seeds, World

In the agricultural business (Crop Science), sales decreased by 3.6 percent (Fx & portfolio adj.) to 3.986 billion euros.

The Bayer Group has reported third-quarter sales that were level with the prior-year period on a currency- and portfolio-adjusted basis (Fx & portfolio adj.), while earnings declined. In the agricultural business (Crop Science), sales decreased by 3.6 percent (Fx & portfolio adj.) to 3.986 billion euros. Sales of glyphosate-based herbicides declined by 19.1 percent (Fx & portfolio adj.) as purchasing patterns normalised and volumes decreased as a result, while a significant acreage reduction for corn in Latin America contributed to a similar decline in global sales of the Corn Seed & Traits business (Fx & portfolio adj. 19.3 percent). These negative effects were partially offset by substantially increased fungicide and insecticide sales, with growth rates of 13.1 percent and 9.5 percent (Fx & portfolio adj.), respectively.

EBITDA before special items at Crop Science increased to 35 million euros (Q3 2023: minus 24 million euros), mainly due to lower provisions for the Group-wide short-term incentive (STI) program and a decrease in the cost of goods sold. Earnings were negatively impacted by the slight decline in sales. There was a positive currency effect of 32 million euros (Q3 2023: 121 million euros).

“The development of the agricultural market has been weaker than anticipated, especially in Latin America, and the company also continues to face pricing pressure in the crop protection business, he said. Bayer is therefore lowering its 2024 targets for Crop Science. For 2025, Bayer is cautious on the agricultural market environment. Additional regulatory challenges and generic pricing pressures are set to put pressure on the crop protection business”, said Bill Anderson, Chief Executive Officer, Bayer.

In the agricultural business (Crop Science), sales

Agro chems – Chemicals, Company News, Europe, People

Bill Anderson, a chemical engineer by education, has served in various leadership positions in the life science industry over the past 25 years.

 The Supervisory Board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board of Management on April 1, 2023. Bill Anderson was elected unanimously after a thorough selection process which began mid last year. Werner Baumann (60), current CEO of Bayer, will work closely with him on a smooth transition before retiring from Bayer after 35 years of service at the end of May 2023.

Bill Anderson (56), a chemical engineer by education, has served in various leadership positions in the life science industry over the past 25 years. Bill Anderson holds a Bachelor of Science in Chemical Engineering from the University of Texas, and Master of Science degrees in Chemical Engineering and Management from the Massachusetts Institute of Technology (MIT).

Most recently, he served as CEO of Roche’s Pharmaceuticals Division, where he successfully led a comprehensive transformation program which resulted in many successful new product launches, significant revenue growth, and greater productivity across the organization. Before this role, Anderson was CEO of Genentech, one of the pioneering companies in the biotech field.

Previously, Bill Anderson held several senior leadership positions in general management, product development, and finance at Biogen, another innovation leader in the biotech sphere, and Raychem, an American technology and electronics company. During his time at Biogen, Genentech, and Roche, Anderson was involved in the development and launch of 25 new medicines, including 15 blockbusters. In addition to his native country, the United States, Bill Anderson has lived and worked in several European countries with postings in the United Kingdom, the Netherlands, Belgium, and Switzerland. In his new role, he will be based in Leverkusen, Germany.

“We are very excited to welcome Bill Anderson as new CEO of Bayer. He is the ideal candidate to lead Bayer together with the team into a new, successful chapter at a time of a disruptive innovation cycle in biology, chemistry, and artificial intelligence. Bill has an outstanding track record of building strong product pipelines and turning biotech breakthroughs into products. Beyond that, he is a truly transformational leader who creates a culture that propels innovation, boosts productivity and performance, and allows people to thrive,” said Prof. Dr Norbert Winkeljohann, Chairman of the Supervisory Board of Bayer AG.

The new CEO-elect, Bill Anderson, said: “Bayer is an innovative company that is already delivering tremendous benefits for the nutrition, health, and environmental protection of the world. Its leading R&D investments in agriculture, medicines and consumer health hold the promise for additional breakthroughs. I look forward to working with the people of Bayer to accelerate innovation, increase performance, advance sustainability, and unleash the full potential of the company.”

Bill Anderson, a chemical engineer by education,